Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 93

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 93
---
                                                                       |

| ● | our anticipated use of                   
 the net proceeds from this offering; and |

| ● | statements as to the impact                                                                                                            
 of the political and security situation in Israel on our business, including due to war or conflicts between Israel, Hamas, Hezbollah, 
 and on other fronts from various extremist groups in the region, such as the Houthis in Yemen and various rebel militia groups in      
 Syria and Iraq.                                                                                                                        |

Forward-looking statements
are based on our management’s current expectations, estimates, forecasts and projections about our business and the industry in
which we operate and our management’s beliefs and assumptions, and are not guarantees of future performance or development and
involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of
our forward-looking statements in this prospectus may turn out to be inaccurate. Important factors that may cause actual results to differ
materially from current expectations include, among other things, those listed under “Risk Factors” and elsewhere in this
prospectus. Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements.

The forward-looking statements
included in this prospectus speak only as of the date of this prospectus. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances
reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we assume no obligation to update
or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however,
review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus.
See “Where You Can Find More Information.”

<div align='center'>57

USE OF PROCEEDS</div>

We expect to receive approximately $8 million in net proceeds
from the sale of Ordinary Shares offered by us in this offering (approximately $9.4 million if the Representative’s
exercises its over-allotment option in full), based upon an assumed public offering price of $11.00 per Ordinary Share, which is
the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the underwriting discounts and commissions
and estimated offering expenses payable by us.

Each $0.25 increase or decrease
in the assumed initial public offering price of $11